Furthermore, it has been reported that the levels of α2AP are also elevated in patients with rheumatic diseases other than SLE,47, 48, 49, 50 and the blockade of α2AP attenuates the disease severity in systemic sclerosis (SSc) model mice and SSc fibroblasts.47, 51. This evidence concerns the gene SERPINF2 and systemic lupus erythematosus.